Asia-Pacific Nucleic Acid Therapeutics CDMO Market - Analysis and Forecast, 2023-2033

1.1 Global Market Outlook
1.1.1 Market Overview
1.1.2 Product Definition
1.1.3 Inclusion and Exclusion Criteria
1.1.4 Key Findings
1.2 Industry Outlook
1.2.1 Key Trends
1.2.1.1 Significant Number of Collaborations among Market Players
1.2.1.2 Increasing Investment for Expansion of Nucleic Acid Therapeutics CDMO Manufacturing Units
1.2.1.3 CDMOs Shifting their Business Strategy in Response to a Changing Environment
1.2.2 Opportunity Assessment
1.2.3 Preferred Techniques By CDMO
1.2.3.1 Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
1.2.3.2 Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
1.2.3.3 Preferred Techniques by CDMOs for Nucleic Acid Purification
1.2.4 Factors Considered While Outsourcing To CDMO.
1.3 Impact of COVID-19 on the Global Nucleic Acid Therapeutics CDMO
1.3.1 Pre-COVID-19 Phase
1.3.2 During COVID-19
1.3.3 Post-COVID-19 Phase
1.3.3.1 Impact on Demand and Supply
1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
1.5 Significant Usage of Nucleic Acid in Therapeutics
1.6 Types of Nucleic Acid Synthesized for Therapeutics
1.6.1 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
1.6.2 RNA Interference (RNAi) and Short Interfering RNAs (siRNAs)
1.6.3 MicroRNAs (miRNAs)
1.6.4 RNA Aptamers and RNA Decoys
1.6.5 Ribozymes
1.6.6 Circular RNAs
1.7 Business Dynamics
1.7.1 Impact Analysis
1.7.2 Business Drivers
1.7.2.1 Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases
1.7.2.2 Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics
1.7.2.3 Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs
1.7.3 Business Restraints
1.7.3.1 Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification
1.7.3.2 Lack of Expertise in Developing Nucleic Acid Therapeutic
1.7.4 Business Opportunities
1.7.4.1 Continued Research and Development Activities for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses.
1.7.4.2 Pharmaceutical Firms Becoming More Outsourcing-Oriented

2.1 Asia-Pacific Nucleic Acid Therapeutics CDMO Market
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.2.1 Impact Analysis
2.1.3 Market Sizing and Forecast
2.1.3.1 Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2 Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Country)
2.1.3.2.1 Japan
2.1.3.2.1.1 Japan Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2.2 China
2.1.3.2.2.1 China Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2.3 India
2.1.3.2.3.1 India Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2.4 Australia
2.1.3.2.4.1 Australia Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2.5 Rest-of-Asia-Pacific
2.1.3.2.5.1 Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)

3.1 Competitive Benchmarking
3.1.1 Key Strategies and Developments
3.1.1.1 Funding Activities
3.1.1.2 New Offerings
3.1.1.3 Mergers and Acquisitions
3.1.1.4 Partnerships and Collaborations
3.1.1.5 Business Expansions
3.1.1.6 Regulatory and Legal Activities
3.1.2 Market Share Analysis
3.1.3 Visual Graphics of Key Companies
3.2 Company Profile
3.2.1 Asymchem Inc.
3.2.1.1 Company Overview
3.2.1.2 Role of Asymchem Inc. in the Nucleic Acid Therapeutics CDMO Market
3.2.1.3 Financials
3.2.1.4 Recent Developments
3.2.1.5 Analyst Perspective
3.2.2 BioCina
3.2.2.1 Company Overview
3.2.2.2 Role of BioCina in the Nucleic Acid Therapeutics CDMO Market
3.2.2.3 Recent Developments
3.2.2.4 Analyst Perspective
3.2.3 CMIC HOLDINGS Co., Ltd.
3.2.3.1 Company Overview
3.2.3.2 Role of CMIC HOLDINGS Co., Ltd. In the Nucleic Acid Therapeutics CDMO Market
3.2.3.3 Financials
3.2.3.4 Analyst Perspective
3.2.4 Kaneka Corporation
3.2.4.1 Company Overview
3.2.4.2 Role of Kaneka Corporation in the Nucleic Acid Therapeutics CDMO Market
3.2.4.3 Financials
3.2.4.4 Recent Developments
3.2.4.5 Analyst Perspective
3.2.5 Nippon Shkubai Co., Ltd
3.2.5.1 Company Overview
3.2.5.2 Role of Nippon Shokubai Co., Ltd in the Nucleic Acid Therapeutics CDMO Market
3.2.5.3 Financials
3.2.5.4 Analyst Perspective
3.2.6 Nitto Group
3.2.6.1 Company Overview
3.2.6.2 Role of Nitto Group in the Nucleic Acid Therapeutics CDMO Market
3.2.6.3 Financials
3.2.6.4 Recent Developments
3.2.6.5 Analyst Perspective
3.2.7 ST Pharm
3.2.7.1 Company Overview
3.2.7.2 Role of ST Pharm in the Nucleic Acid Therapeutics CDMO Market
3.2.7.3 Financials
3.2.7.4 Recent Developments
3.2.7.5 Analyst Perspective

Figure 1: Services Offered by CDMOs
Figure 2: Nucleic Acid Therapeutics CDMO Market, Impact Analysis
Figure 3: Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), % Share, 2022 and 2033
Figure 4: Nucleic Acid Therapeutics CDMO Market (by Region), $Billion, 2022 and 2033
Figure 5: Nucleic Acid Therapeutics CDMO Market: Research Methodology
Figure 6: Primary Research Methodology
Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
Figure 8: Top-Down Approach (Segment-Wise Analysis)
Figure 9: Significant Number of Collaborations among Market Players in Nucleic Acid Therapeutics CDMO Market, 2019-2023
Figure 10: Core CDMO Services
Figure 11: Nucleic Acid Therapeutics CDMO Market Key Trends, Market Shift, 2022-2033
Figure 12: Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
Figure 13: Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
Figure 14: Preferred Techniques by CDMOs for Nucleic Acid Purification
Figure 15: Factors considered while outsourcing to CDMO.
Figure 16: Nucleic Acid Therapeutics CDMO Market, Impact Analysis
Figure 17: Significant Increase in Sale of TEGSEDI and WAYLIVRA Drugs in $Million, 2018-2021
Figure 18: Significant Number of Nucleic Acid Drugs Approved by FDA or EMA in Global Nucleic Acid Therapeutics CDMO Market, 2018-2020
Figure 19: Nucleic Acid Therapeutics CDMO Market Share (by Region), 2022-2033
Figure 20: Incidence of Hematologic Malignancies, Asia, 2020 vs. 2040
Figure 21: Asia-Pacific Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 22: Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 23: Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Country), % Share, 2022 and 2033
Figure 24: Japan Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 25: Japan Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 26: China Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 27: China Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 28: India Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 29: India Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 30: Australia Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 31: Australia Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 32: Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 33: Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 34: Global Nucleic Acid Therapeutics CDMO Market, Number of Key Developments and Strategies, January 2018-February 2023
Figure 35: Funding Activities, January 2018-February 2023
Figure 36: New Offerings, January 2018-February 2023
Figure 37: Mergers and Acquisitions, January 2018-February 2023
Figure 38: Partnerships and Collaborations, January 2018-February 2023
Figure 39: Business Expansions, January 2018-February 2023
Figure 40: Regulatory and Legal Activities, January 2018-February 2023
Figure 41: Global Nucleic Acid Therapeutics CDMO Market, Company Revenue Share Analysis, $Billion, 2022
Figure 42: Some of the Active Players in the Nucleic Acid Therapeutics CDMO Market
Figure 43: Asymchem Inc.: Product Portfolio
Figure 44: Asymchem Inc.: Overall Financials, $Million, 2021-2022
Figure 45: Asymchem Inc.: Net Revenue (by Segment), $Million, 2021-2022
Figure 46: Asymchem Inc.: Net Revenue (by Region), $Million, 2021-2022
Figure 47: Asymchem Inc.: R&D Expenditure, $Million, 2021-2022
Figure 48: BioCina: Product Portfolio
Figure 49: CMIC HOLDINGS Co., Ltd.: Product Portfolio
Figure 50: CMIC HOLDINGS Co., Ltd.: Overall Financials, $Million, 2020-2022
Figure 51: CMIC HOLDINGS Co., Ltd.: Segment Revenues, $Million, 2020-2022
Figure 52: CMIC HOLDINGS Co., Ltd.: Net Revenue (by Region), $Million, 2020-2022
Figure 53: CMIC HOLDINGS Co., Ltd.: R&D Expenditure, $Million, 2020-2022
Figure 54: Kaneka Corporation: Product Portfolio
Figure 55: Kaneka Corporation: Overall Financials, $Million, 2019-2021
Figure 56: Kaneka Corporation: Net Revenue (by Segment), $Million, 2019-2021
Figure 57: Kaneka Corporation: Net Revenue (by Region), $Million, 2019-2021
Figure 58: Kaneka Corporation: R&D Expenditure, $Million, 2019-2021
Figure 59: Nippon Shokubai Co., Ltd: Product Portfolio
Figure 60: Nippon Shokubai Co., Ltd: Overall Financials, $Million, 2019-2021
Figure 61: Nippon Shokubai Co., Ltd: Segment Revenues, $Million, 2019-2021
Figure 62: Nitto Group: Product Portfolio
Figure 63: Nitto Group: Overall Financials, $Million, 2019-2021
Figure 64: Nitto Group: Segment Revenues, $Million, 2019-2021
Figure 65: Nitto Group: Net Revenue (by region), $Million, 2019-2021
Figure 66: Nitto Group: R&D Expenditure, $Million, 2019-2021
Figure 67: ST Pharm: Product Portfolio
Figure 68: ST Pharm: Overall Financials, $Million, 2019-2021
Figure 69: ST Pharm: Net Revenue (by Segment), $Million, 2019-2021

Table 1: Nucleic Acid Therapeutics CDMO Market, Key Developments Analysis, January 2018-February 2023
Table 2: Key Questions Answered in the Report
Table 3: Some of the Partnerships and Collaborations in the Global Nucleic Acid Therapeutics CDMO Market
Table 4: Nucleic Acid Therapeutics CDMO Market, Key Investment
Table 5: Nucleic Acid Drugs Approved by FDA or EMA, 2018-2021
Table 6: Advancements in Manufacturing Units of CDMO
Table 7: Asia-Pacific Nucleic Acid Therapeutics CDMO Market, Impact Analysis